Drug-resistance to ofloxacin (OFX) in Mycobacterium tuberculosis is due to missense mutations in gyrA and other factors, such as alterations in the activity of drug efflux pumps. In this study, we identified 8 extensively drug resistant tuberculosis (XDR-TB), 40 multidrug resistant TB (MDR-TB), 38 polydrug resistant TB (PDR-TB), and 16 single OFX-resistant TB from 102 clinical isolates. We tested the effect of three efflux inhibitors, reserpine, verapamil, and carbonyl cyanide m-chlorophenyl hydrazone (CCCP), on changes in the OFX minimum inhibitory concentration (MIC) using Resazurin microtitre assay. These three inhibitors changed the MICs from 2- to 32-fold, with CCCP having the strongest effect. A total of 55%, 74%, and 83% of the tested isolates had changes in MIC of more than two-fold by reserpine, verapamil, and CCCP, respectively. The inhibitors led to similar fold-changes of OFX MICs in the XDR, MDR, PDR, and single OFX-resistant isolates. For each inhibitor, a higher resistance to OFX was associated with the greater efflux pump activity. There were no significant differences in the effect of efflux pump inhibitors upon Beijing and non-Beijing M. tuberculosis genotypes. Taken together, these results indicate that the efflux pump activity was greater in the isolates higher resistant to OFX and had similar effects on isolates with different drug resistant pattern, and had similar effects on Beijing and non-Beijing genotypes.
Get full access to this article
View all access options for this article.
References
1.
AmaralL., MartinsM., and ViveirosM.. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother., 59:1237–1246.
2.
BanerjeeS.K., BhattK., RanaS., MisraP., and ChakrabortiP.K.. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun., 226:362–368.
3.
ChatterjeeA., SaranathD., BhatterP., and MistryN.. 2013. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One, 8:e54717.
4.
ColangeliR., HelbD., SridharanS., SunJ., Varma-BasilM., HazbónMH., HarbacheuskiR.. Megjugorac N.J., acobsW.R.Jr., HolzenburgA., SacchettiniJ.C., and AllandD.. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol., 55:1829–1840.
5.
Committee of Chinese anti-Tuberculosis Association. 2006. Chinese Anti-Tuberculosis Association Protocols for tuberculosis diagnosis in laboratory. 1st. Beijing: Chinese Educational and Cultural Publisher.
6.
De RossiE., AinsaJ.A., and RiccardiG.. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev., 30:36–52.
7.
De RossiE., ArrigoP., BellinzoniM., SilvaP.A., MartìnC., AínsaJ.A., GuglierameP., and RiccardiG.. 2002. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol. Med., 8:714–724.
8.
EscribanoI., RodríguezJ.C., LlorcaB., García-PachonE., RuizM., and RoyoG.. 2007. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy, 53:397–401.
9.
FattoriniL., IonaE., RicciM.L., ThoresenO.F., OrrùG., OggioniM.R., TortoliE., PiersimoniC., ChiaradonnaP., TronciM., PozziG., and OreficiG.. 1999. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist., 5:265–270.
10.
GuptaA.K., ChauhanD.S., SrivastavaK., DasR., BatraS., MittalM., GoswamiP., SinghalN., SharmaV.D., VenkatesanK., HasnainS.E., and KatochV.M.. 2006. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. Commun. Dis., 38:246–254.
11.
GuptaS., TyagiS., AlmeidaD.V., MaigaM.C., AmmermanN.C., and BishaiW.R.. 2013. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med., 188:600–607.
12.
HatfullG.F., and JacobsW.R.Jr.2000. Molecular Genetics of Mycobacteria. Washington DC: ASM Press, pp. 235–256.
13.
HelalZ.H., AshourM.S., EissaS.A., Abd-ElatefG., ZozioT., BabapoorS., RastogiN., and KhanM.I.. 2009. Unexpectedly high proportion of ancestral Manu genotype Mycobacterium tuberculosis strains cultured from tuberculosis patients in Egypt. J. Clin. Microbiol., 47:2794–2801.
14.
KamerbeekJ., SchoulsL., KolkA., van AgterveldM., van SoolingenD., KuijperS., BunschotenA., MolhuizenH., ShawR., GoyalM., and van EmbdenJ.. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol., 35:907–914.
15.
LiX.Z., ZhangL., and NikaidoH.. 2004. Efflux pump-mediated intrinsic drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 48:2415–2423.
16.
LongQ., LiW., DuQ., FuY., LiangQ., HuangH., and XieJ.. 2012. gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. Int. J. Antimicrob. Agents., 39:486–489.
17.
LouwG.E., WarrenR.M., van PittiusN.C., LeonR., JimenezA., Hernandez-PandoR., McEvoyC.R., GrobbelaarM., MurrayM., van HeldenP.D., and VictorT.C.. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med., 184:269–276.
18.
MachadoD., CoutoI., PerdigãoJ., RodriguesL., PortugalI., BaptistaP., VeigasB., AmaralL., and ViveirosM.. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One, 7:e34538.
19.
MalikS., WillbyM., SikesD., TsodikovO.V., and PoseyJ.E.. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One, 7:e39754.
20.
MartinA., CamachoM., PortaelsF., and PalominoJ.C.. 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple and inexpensive method. Antimicrob. Agents Chemother., 47:3616–3619.
21.
MukherjeeJ.S., RichM.L., SocciA.R., JosephJ.K., VirúF.A., ShinS.S., FurinJ.J., BecerraM.C., BarryD.J., KimJ.Y., BayonaJ., FarmerP., Smith FawziM.C., and SeungK.J.. 2004. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet., 363:474–481.
22.
Nebenzahl-GuimaraesH., JacobsonK.R., FarhatM.R., and MurrayM.B.. 2013. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother., 69:331–342.
23.
PascaM.R., GuglierameP., ArcesiF., BellinzoniM., De RossiE., and RiccardiG.. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 48:3175–3178.
24.
PillayM., and SturmA.W.. 2007. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis., 45:1409–1414.
25.
RyanB.M., DoughertyT.J., BeaulieuD., ChuangJ., DoughertyB.A., and BarrettJ.F.. 2001. Efflux in bacteria: what do we really know about it?. Expert Opin. Investig. Drugs, 10:1409–1422.
26.
SchmalstiegA.M., SrivastavaS., BelkayaS., DeshpandeD., MeekC., LeffR., van OersN.S., and GumboT.. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob. Agents Chemother., 56:4806–4815.
27.
SinghM., JadaunG.P., Ramdas, SrivastavaK., ChauhanV., MishraR., GuptaK., NairS., ChauhanD.S., SharmaV.D., VenkatesanK., and KatochV.M.. 2011. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res., 133:535–540.
28.
SinghR., SwickM.C., LedesmaK.R., YangZ., HuM., ZechiedrichL., and TamV.H.. 2012. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob. Agents. Chemother., 56:1680–1685.
29.
SulochanaS, NarayananS., ParamasivanC.N., SuganthiC., and NarayananP.R.. 2007. Analysis of fluoroqunolone resistance in clinical isolates of Mycobacterium tuberculosis from India. J. Chemother., 19:89–93.
30.
SunZ., ZhangJ., SongH., ZhangX., LiY., TianM., LiuY., ZhaoY., and LiC.. 2010. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. Int. J. Tuberc. Lung Dis., 14:1436–1441.
31.
SunZ., ZhangJ., ZhangX., WangS., ZhangY., and LiC.. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents, 31:115–121.
32.
TaoJ., HanJ., WuH., HuX.., DengJ.., FlemingJ.., MaxwellA., BiL., and MiK.. 2013. Mycobacterium fluoroquinolone resistance protein B, a novel small GTPase, is involved in the regulation of DNA gyrase and drug resistance. Nucleic Acids Res., 41:2370–2381.
33.
[WHO] World Health Organization 2008. World Health Organization. 2008. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva, WHO, 2008 (WHO/HTM/TB/2008.392) Available at www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf. (Accessed 25February2012).
XuC., KreiswirthB.N., SreevatsanS., MusserJ.M., and DrlicaK.. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis., 174:1127–1130.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
